PMID- 26009893 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20220330 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 5 DP - 2015 TI - Genotypic and phenotypic characterization of P23H line 1 rat model. PG - e0127319 LID - 10.1371/journal.pone.0127319 [doi] LID - e0127319 AB - Rod-cone dystrophy, also known as retinitis pigmentosa (RP), is the most common inherited degenerative photoreceptor disease, for which no therapy is currently available. The P23H rat is one of the most commonly used autosomal dominant RP models. It has been created by incorporation of a mutated mouse rhodopsin (Rho) transgene in the wild-type (WT) Sprague Dawley rat. Detailed genetic characterization of this transgenic animal has however never been fully reported. Here we filled this knowledge gap on P23H Line 1 rat (P23H-1) and provide additional phenotypic information applying non-invasive and state-of-the-art in vivo techniques that are relevant for preclinical therapeutic evaluations. Transgene sequence was analyzed by Sanger sequencing. Using quantitative PCR, transgene copy number was calculated and its expression measured in retinal tissue. Full field electroretinography (ERG) and spectral domain optical coherence tomography (SD-OCT) were performed at 1-, 2-, 3- and 6-months of age. Sanger sequencing revealed that P23H-1 rat carries the mutated mouse genomic Rho sequence from the promoter to the 3' UTR. Transgene copy numbers were estimated at 9 and 18 copies in the hemizygous and homozygous rats respectively. In 1-month-old hemizygous P23H-1 rats, transgene expression represented 43% of all Rho expressed alleles. ERG showed a progressive rod-cone dysfunction peaking at 6 months-of-age. SD-OCT confirmed a progressive thinning of the photoreceptor cell layer leading to the disappearance of the outer retina by 6 months with additional morphological changes in the inner retinal cell layers in hemizygous P23H-1 rats. These results provide precise genotypic information of the P23H-1 rat with additional phenotypic characterization that will serve basis for therapeutic interventions, especially for those aiming at gene editing. FAU - Orhan, Elise AU - Orhan E AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Dalkara, Deniz AU - Dalkara D AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Neuille, Marion AU - Neuille M AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Lechauve, Christophe AU - Lechauve C AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Michiels, Christelle AU - Michiels C AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Picaud, Serge AU - Picaud S AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Leveillard, Thierry AU - Leveillard T AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Sahel, Jose-Alain AU - Sahel JA AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, DHU ViewMaintain, INSERM-DHOS CIC 1423, Paris, France; Institute of Ophthalmology, University College of London, London, United Kingdom; Fondation Ophtalmologique Adolphe de Rothschild, Paris, France; Academie des Sciences, Institut de France, Paris, France. FAU - Naash, Muna I AU - Naash MI AD - Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America. FAU - Lavail, Matthew M AU - Lavail MM AD - Department of Ophthalmology, University of California San Francisco, San Francisco, California, United States of America; Department of Anatomy, University of California San Francisco, San Francisco, California United States of America. FAU - Zeitz, Christina AU - Zeitz C AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France. FAU - Audo, Isabelle AU - Audo I AD - INSERM, U968, Paris, France; CNRS, UMR_7210, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, Paris, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, DHU ViewMaintain, INSERM-DHOS CIC 1423, Paris, France; Institute of Ophthalmology, University College of London, London, United Kingdom. LA - eng GR - R01 EY010609/EY/NEI NIH HHS/United States GR - EY10609/EY/NEI NIH HHS/United States GR - F32 EY006842/EY/NEI NIH HHS/United States GR - R01 EY006842/EY/NEI NIH HHS/United States GR - R01 EY001919/EY/NEI NIH HHS/United States GR - R56 EY010609/EY/NEI NIH HHS/United States GR - EY001919/EY/NEI NIH HHS/United States GR - EY006842/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20150526 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 9009-81-8 (Rhodopsin) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Color Vision MH - Disease Models, Animal MH - Electroretinography MH - Gene Dosage MH - Hemizygote MH - Molecular Sequence Data MH - Mutation/genetics MH - Phenotype MH - Rats, Sprague-Dawley MH - Rats, Transgenic MH - Retina/pathology MH - Retinitis Pigmentosa/*genetics MH - Rhodopsin/chemistry/*genetics MH - Sequence Analysis, DNA MH - Tomography, Optical Coherence MH - Transgenes PMC - PMC4444340 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/05/27 06:00 MHDA- 2016/04/19 06:00 PMCR- 2015/05/26 CRDT- 2015/05/27 06:00 PHST- 2015/01/21 00:00 [received] PHST- 2015/04/13 00:00 [accepted] PHST- 2015/05/27 06:00 [entrez] PHST- 2015/05/27 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] PHST- 2015/05/26 00:00 [pmc-release] AID - PONE-D-14-57446 [pii] AID - 10.1371/journal.pone.0127319 [doi] PST - epublish SO - PLoS One. 2015 May 26;10(5):e0127319. doi: 10.1371/journal.pone.0127319. eCollection 2015.